Clinical Trial Update: Polypill Effects on Sub Clinical Atherosclerosis (PESCA) Trial [Phase 3]

View source ↗

Summary

Phase 3 trial PESCA investigating polypill effects on subclinical atherosclerosis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Snippet

Sponsor: Imperial College London | Conditions: Cardiovascular Disease | Phase 3 | Status: WITHDRAWN